BioLight Life Sciences Ltd (BOLT) Fair Value & Analysis
Healthcare · Il · Market cap 24.2M ILA
Fair value as of: Jun 25, 2026
From 1 valuation models · updated 19 days ago
Share price +27.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 2.12 ILA – 5.97 ILA · fair‑value band 1.02 ILA – 1.92 ILA · the 3.70 ILA price screens above the 1.54 ILA fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
BioLight Life Sciences Ltd (BOLT) currently trades at 3.70 ILA, while our model-based Fair Value estimate is 1.54 ILA — implying the stock looks roughly 58.4% overvalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 21.0K ILA. Revenue grew 25.0% year over year. It earns a return on equity of -48.4%. The balance sheet holds a net cash position of 3.2M ILA. Fundamentals as of Jun 25, 2026
Our scenario range runs from 1.02 ILA (bear case) to 1.92 ILA (bull case); at 3.70 ILA, the current price sits above that range. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -58%, BOLT screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx Dry Eye Syndrome; and Ocuvia, a front-to-back ocular treatment that includes ocudrip and ocugrid. It also provides Eye-D technology which treats glaucoma by the insertion of a sub-conjunctival implant; and Ocular D, a product for treating dryness in the eye with integrated vitamin D. In addition, the company engages in the development of drugs for treating eye diseases using a technological platform that enhances the transmission of active substances based on nanostructures. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BioLight Life Sciences Ltd reported revenue of 0 ILA in FY2025 versus 3.0K ILA in FY2021. Reported net income was −11.7M ILA in FY2025.
Is BOLT fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.04 | R$46.95 | -10% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$14.75 | R$4.91 | -67% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BioLight Life Sciences Ltd (BOLT) undervalued?
What is the fair value of BOLT?
What is the quality score of BOLT?
What is the revenue of BioLight Life Sciences Ltd (BOLT)?
What is the net profit margin of BOLT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full BioLight Life Sciences Ltd analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.